Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
Source: Article title. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
Study design awaiting verification · JCEM Case Reports · 2025
Original publication title
Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Extraosseous giant cell tumor of bone (GCTB) associated with Paget disease of bone (PDB) is rare. We report a patient aged in their 70s with polyostotic PDB involving the skull, spine, and pelvis, previously treated with bisphosphonates, who presented with symptomatic hypercalcemia (calcium 14.8 mg/dL [3.7 mmol/L]; reference range [RR], 8.6-10.5 mg/dL [2.1-2.6 mmol/L]), kidney injury (creatinine 2.6 mg/dL [230 μmol/L]; RR, 0.4-1.1 mg/dL [35-97 μmol/L]), and a 17.5 cm pelvic mass. Testing showed elevated calcitriol or 1,25-dihydroxyvitamin D (1,25(OH)2D) (57-108 pg/mL [137-259 pmol/L]; RR, 18-72 pg/mL [43-173 pmol/L]), but normal parathyroid hormone and bone-specific alkaline phosphatase (BSAP), arguing against parathyroid autonomy and active osseous PDB.
Histopathology showed osteoclast-like giant cells and stromal mononuclear cells without atypia, necrosis, or mitoses. A one-time dose of denosumab 120 mg resulted in normalized calcium (9.0 mg/dL [2.2 mmol/L]) and 1,25(OH)2D (24 pg/mL [57 pmol/L]) and reduced tumor size. Denosumab was continued at a dose of 60 mg every 6 months. After 20 months, calcium and 1,25(OH)2D remained normal, with no tumor regrowth, and BSAP stayed low. This is the first report of 1,25(OH)2D-mediated hypercalcemia in extraosseous GCTB.
It responded well to denosumab. Long-term management options are discussed in the context of existing literature.
Authors’ abstract
Abstract
Extraosseous giant cell tumor of bone (GCTB) associated with Paget disease of bone (PDB) is rare. We report a patient aged in their 70s with polyostotic PDB involving the skull, spine, and pelvis, previously treated with bisphosphonates, who presented with symptomatic hypercalcemia (calcium 14.8 mg/dL [3.7 mmol/L]; reference range [RR], 8.6-10.5 mg/dL [2.1-2.6 mmol/L]), kidney injury (creatinine 2.6 mg/dL [230 μmol/L]; RR, 0.4-1.1 mg/dL [35-97 μmol/L]), and a 17.5 cm pelvic mass. Testing showed elevated calcitriol or 1,25-dihydroxyvitamin D (1,25(OH)2D) (57-108 pg/mL [137-259 pmol/L]; RR, 18-72 pg/mL [43-173 pmol/L]), but normal parathyroid hormone and bone-specific alkaline phosphatase (BSAP), arguing against parathyroid autonomy and active osseous PDB.
Histopathology showed osteoclast-like giant cells and stromal mononuclear cells without atypia, necrosis, or mitoses. A one-time dose of denosumab 120 mg resulted in normalized calcium (9.0 mg/dL [2.2 mmol/L]) and 1,25(OH)2D (24 pg/mL [57 pmol/L]) and reduced tumor size. Denosumab was continued at a dose of 60 mg every 6 months. After 20 months, calcium and 1,25(OH)2D remained normal, with no tumor regrowth, and BSAP stayed low. This is the first report of 1,25(OH)2D-mediated hypercalcemia in extraosseous GCTB.
It responded well to denosumab. Long-term management options are discussed in the context of existing literature.
Publication and source details
Original title: Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease
Oyunbileg Magvanjav; Clemens Bergwitz
JCEM Case Reports · 2025
Correspondence: Clemens Bergwitz, MD, Section of Endocrinology and Metabolism, Anlyan Center, Yale University School of Medicine, Office S117, Lab S130, 1 Gilbert Street, New Haven, CT 06519, USA. Email: clemens.bergwitz@yale.edu.© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. National Institutes of Health10.13039/100000002 T32DK007058-50Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T02:27:41.910971+00:00
DOI: 10.1210/jcemcr/luaf031 · PMC11920620